Radiotherapy regimens and concurrent Cabergoline use for non-functioning pituitary neuroendocrine tumors: a large, single-center cohort. [PDF]
Mauro GP +8 more
europepmc +1 more source
Cabergoline monotherapy in GH- and PRL-cosecreting pituitary adenomas. [PDF]
McNeil JM +3 more
europepmc +1 more source
Successful response to cabergoline treatment in a non-diabetic cat with hypersomatotropism and pituitary macroadenoma. [PDF]
Márquez Conde CA, Miceli DD.
europepmc +1 more source
A novel germline CDH23 variant as a likely cause of an ultra-giant prolactinoma. [PDF]
Albasri E +7 more
europepmc +1 more source
Combined treatment of pegvisomant and cabergoline in a cat with hypersomatotropism: insulin-like growth factor 1 normalization and control of comorbidities. [PDF]
Miceli DD +5 more
europepmc +1 more source
Editorial Expression of Concern: Does Cabergoline help in decreasing endometrioma size compared to LHRH agonist? A prospective randomized study. [PDF]
Hamid AMSA +4 more
europepmc +1 more source
A Woman's Infertility Journey Complicated by Severe Ovarian Hyperstimulation Syndrome - A Case Report. [PDF]
Khetani S, Hutchison J, Lee CM.
europepmc +1 more source
The Differences Between Dopamine Agonist-Resistant and -Non-Resistant Prolactinomas: Are There Any Predictors of a Good Response? [PDF]
Komisarz-Calik M +9 more
europepmc +1 more source
Evanescent Hyperemia: An Underrecognized Cutaneous Manifestation of Postural Orthostatic Tachycardia Syndrome. [PDF]
Ilyas MU, Barlas S, Abid M, Hussain M.
europepmc +1 more source
Prolactinoma localization by inferior petrosal sinus sampling: illustrative case. [PDF]
Ahmed AK +8 more
europepmc +1 more source

